Clinical Perspectives and Targeted Therapies in Apoptosis: Drug Discovery, Drug Delivery, and Disease Prevention provides comprehensive coverage, from basic cell biology, to modern assessment techniques for apoptosis in all major disease areas. Chapters provide an introduction to the fundamentals of cell biology, biochemical mechanisms, and the pathophysiological consequences of apoptosis. In addition, the book covers the tools and techniques used to quantify apoptosis and the significance of apoptosis in drug discovery, drug delivery, and its applications in disease prevention. Finally, the book provides a comprehensive compilation of the apoptosis targeting drugs that recently underwent clinical trials.
This combination of fundamentals, along with applications in drug discovery, drug delivery, and clinical research make this book a useful resource for those in both academia and industry who are engaged in pharmaceutical, biomedical and biotechnology research.
- Offers standard and innovative therapeutic approaches to modulate apoptosis in clinical interventions, such as cardiovascular diseases, immune disorders, cancer chemotherapy and neurological ailments
- Covers cutting-edge laboratory techniques and traditional protocols to determine apoptosis, both in vitro and in vivo
- Examines clinical study reports of new drug moieties that are explored for various pathological conditions associated with apoptosis
2. Physiology of Cellular Demise
3. Molecular Pathways of Apoptotic Cell Death
4. Apoptosis: Warrior or Opponent
5. Protocols in apoptosis identification and affirmation
6. Modulating apoptosis in cancer
7. Cardiovascular diseases
8. Recent approaches to target apoptosis in neurological disorders
9. Autoimmune diseases and apoptosis: targets, challenges and innovations
10. Clinical trials of promising apoptosis modulating drugs
Dr. Rupinder K Sodhi's core areas of research cover different segments of neuropharmacology like cognition, dementia and Alzheimer's disease. Central to her research activities involves evaluation of the potential of new chemical entities using advanced in vitro and in vivo tools and techniques. More over her expertise is in the field of neurodegenerative and neuropsychiatric disorders like Alzheimer, depression and also in diabetes and related complications such as neuropathic pain, nephropathy pain and inflammation aiming to deconvolute the novel target sites for drug discovery and development. Currently she is active in evaluating the therapeutic efficacy of controlled and targeted drug delivery systems such as nanomedicine in collaboration with pharmaceutics department.
Dr. Jitender Madan's major areas of research include self-assembled supramolecular systems - liposomes, niosomes, cyclodextrin, nano- and micro-particles and solid-lipid nanoparticles. His focus is on the exploitation of US FDA approved biomaterials in combination with other potential lipids and polymers to develop the innovative dosage forms and drug delivery systems in order to improve the bioavailability, stability, safety (tolerance) and patient-compliance. While a wide range of applications are being considered, special emphasis has been given to augment the aqueous solubility and bioavailability of anticancer drugs as well as on the design, synthesis and development of ligand conjugated stealth nanoconstructs for delivery and targeting of anticancer drugs in cancer cells both in vitro and in vivo.